Looks like this has turned around, nice bowl shape and moving up with confirming daily volume and a confirming weekly MACD.
Re Peakeys question on the Outstanding Breakout alerts thread ... "has longer term resistance been handled at 32ish". IMO this will consolidate around the .335 (this is the target for the slightly messy flag and it corresponds perfectly with a major market turning point in Aug last year) ..... but looking at the current market depth it might fly thru if it chomps yesterdays high of .33 first thing. I'd be watching the volume on open and if it's similar to yesterdays vol for the period it really climbed, it might just continue to break up thru this resistance. I'd keep a tight stop on it tho. If it breaks this bowl pattern I would say the next major resistance will be at 50 to 55ish
Had a quick look throught recent news which looks very promising. Here's a copy of the latest ann. January 10, 2007
Unilife secures regulatory approval for Canada
- Signs a Canadian distribution agreement including first orders for the sale of Unitract 1mL syringe products -
Unilife Medical Solutions Ltd (“Unilife”) (ASX:UNI) is pleased to announce that it has received
regulatory approval from Health Canada for the 1mL Unitract Safe Syringe ("Safe Syringe").
The company is also pleased to announce the signing of a Canadian distribution agreement
("Agreement") for the sale of 1mL Safe and 1mL Insulin Syringes ("1mL syringe products") and,
possibly, other Unitract syringe products, complete with a first order for 1mL syringe products.
Unilife has appointed Angus Medical, a specialist Canadian national distributor of safety medical
devices, as its exclusive partner for the Canadian syringe market. Under the Agreement Angus
Medical must place an immediate order for the purchase of products to commence initial
marketing activities during the first half of 2007. Angus Medical has been in discussion with various
government agencies in Canada that are seeking to evaluate the use of Unitract syringes within
both healthcare and harm reduction markets.
The Agreement also includes a commitment by Angus Medical to purchase a minimum 3 million
1mL syringe products within the first 2 years of the Agreement in order to keep exclusivity for
Canada. The Agreement with Angus Medical for Canada represents the start of the rollout of
regulatory approval, distribution and sales across key international markets. It also represents the
first confirmed order for the sale of Unitract products.
Legislation mandating the use of sharps safety devices within Canadian healthcare facilities to
protect healthcare workers from needlestick injuries has now been adopted, or is in the process of
being approved, by all provincial governments in Canada. These laws, which are similar to those
now in place across the United States, should see the Canadian national market for safety syringes
grow in excess of 10% per annum over the coming years. The Canadian harm reduction market is
among one of the largest and most progressive in the world.
Both Unilife and Angus Medical are confident that the core safety features of the Unitract syringe
products, combined with US production at the facilities of IBS, will generate significant levels of
product demand within Canadian healthcare and harm reduction markets.
Mr Alan Shortall, Chief Executive Officer of Unilife said that the Agreement and the initial order for
Canada was a further indication that international demand for Unitract products was building.
“Unilife welcomes the appointment of Angus Medical as its Canadian distribution partner. We have
selected Angus Medical because of their specialty national expertise in the supply of sharps safety
products and their commitment to establishing Unitract as the premium brand for safety syringes
throughout Canada", said Mr Shortall.
Mr Shortall said “We are delighted with the strong level of interest which has already been secured
for Unitract products within Canadian healthcare and harm reduction markets. The decision by
Angus Medical to commit to minimum sales for Unitract syringes during the term of the Agreement
to ensure it retains exclusivity reflects this positive market feedback, and the ongoing transition of
Canada to the mandatory use of sharps safety products. We look forward to building a strong
long-term business relationship with Angus Medical."
Mr Bruce Robertson, President of Angus Medical said “Canadian healthcare and harm reduction
markets are now ready to transition to the use of safety syringe products. In partnership with local
government and industry leaders in Canada, Angus Medical has conducted an initial review of the
Safe Syringe against other syringe technologies now available. We are confident that the Unitract
syringe products have strong potential across a range of markets in Canada."
“As a fast-growing national supplier of safe and innovative medical devices, we are delighted to
have established this partnership with Unilife. Our sales team are now working with Unilife’s
Clinical specialists to ensure that the planned Canadian market development activities help drive
sales across healthcare, harm reduction and diabetic markets in 2007”, said Mr Robertson.
About Unilife
Unilife Medical Solutions Ltd is an ISO 13485 certified developer and supplier of innovative sharps safety products,
marketed under its premium UnitractTM brand. A publicly listed company on the Australian Stock Exchange
(ASX:UNI), Unilife operates commercial and manufacturing facilities in Sydney, Australia, and has acquired
Integrated BioSciences Inc (IBS), an established contract manufacturer of medical devices with certified cleanroom
facilities in the US State of Pennsylvania. The Unitract portfolio of safety syringes features a range of products which
help to reduce the transfer of blood-borne viruses, and protect those at risk of needlestick injuries. Each product in the
portfolio is custom-designed to meet the safety and functionality needs of a distinct sector of the $4 billion global
syringe market that is now transitioning to the use of sharps safety products. The Unitract range of 1mL safety syringes
are the first products to be manufactured by Unilife, and are designed to encourage safe injection practices within
diabetic, harm reduction and acute-care markets. Unilife is also developing other syringe variants of its patent-protected
Unitract technology suitable for use within healthcare, pharmaceutical and vaccination markets.